GU Cancers 2024 | Enfortumab vedotin for urothelial cancer in the real-world setting

Stefanie Zschaebitz, MD, Heidelberg University Hospital, Heidelberg, Germany, comments on the real-world safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer. In a European cohort, anti-tumor activity comparable to findings in the EV-301 trial (NCT03474107) was observed and adverse events, including peripheral sensory neuropathy and skin toxicity, were generally manageable, with no new safety signals observed. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.